pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,545 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165BioSpace64Fierce Biotech64raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • FDA OKs first new sunscreen ingredient in more than 25 years
    Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.
    STAT · 1mo ago↗ source
  • Eli Lilly's claims data deadline may kick off new 340B fight
    Eli Lilly’s deadline has passed for hospitals to comply with its new 340B claims data policy, and for now the pharma company is staying mum on its next steps. But just because Lilly is declining ...
    Endpoints · 1mo ago↗ source
  • Grace Science says FDA bottleneck jeopardizes rare disease therapy
    Grace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line. Co-founded by Nobel laureate Carolyn Bertozzi…
    Endpoints
← prev
page 27 of 62
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • A different approach to lowering healthcare costs
    Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...
    Endpoints · 1mo ago↗ source
  • Trump administration warns more than 500 hospitals to provide more price information or face fines
    The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.
    STAT · 1mo ago↗ source
  • How K Health moved AI chatbots into hospitals
    Startups that fashion themselves as AI doctors that patients can chat with have gained traction over the last year. One of these startups, K Health, began in 2016 as a symptom checker ...
    Endpoints · 1mo ago↗ source
  • Gilead and Merck’s latest trial success and flop
    AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: NIAID appoints new acting director after weekslong questions over leadership
    The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
    STAT · 1mo ago↗ source
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…
    Endpoints · 1mo ago↗ source
  • Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
    Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…
    Endpoints · 1mo ago↗ source
  • Endpoints Women in Biopharma: Nominate for 2026
    Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…
    Endpoints · 1mo ago↗ source
  • Pharma and biotech salaries: Top-paying companies of 2025
    The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
    GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
    STAT · 1mo ago↗ source
  • Dexcom RCT suggests CGM benefits for broad diabetes population
    In this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.
    STAT · 1mo ago↗ source
  • STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored
    In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns.
    STAT · 1mo ago↗ source
  • STAT+: What’s changed since the last major Ebola outbreak
    A suppressed federal alcohol report, an "inevitable development" for wearables data, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Post-Hoc Live: How much is everyone in biopharma getting paid?
    The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the in…
    Endpoints · 1mo ago↗ source
  • WuXi AppTec added to Pentagon's list of companies linked to Chinese military
    Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...
    Endpoints · 1mo ago↗ source
  • Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
    “Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
    STAT · 1mo ago↗ source
  • STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
    Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
    STAT · 1mo ago↗ source
  • Opinion: Why STAT is sticking with ‘health care’ as two words
    Is it “health care” or “healthcare”? STAT readers had strong feelings.
    STAT · 1mo ago↗ source
  • STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
    Hospital execs say they're working to mitigate the impacts of the looming cuts.
    STAT · 1mo ago↗ source
  • A leader of the 2014 U.S. Ebola response compares then to now
    As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
    STAT · 1mo ago↗ source
  • STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
    GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
    STAT · 1mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugm…
    Endpoints · 1mo ago↗ source